Making on-line science course materials easily translatable and accessible worldwide: Challenges and solutions

The PhET Interactive Simulations Project recently partnered with the Excellence Center of Science and Mathematics Education at King Saud University with the joint goal of making simulations available worldwide. One of the main challenges of this partnership is to make PhET simulations easily translatable so that truly anyone with a computer can use them in their classroom. The PhET project team has created the Translation Utility that allows a person, who is fluent in both English and another language, to easily translate any of the PhET simulations. This can be done with minimal computer expertise, making the translation process accessible to faculty and teachers. In this presentation we will share solutions to many of the unexpected problems we encountered that would apply in general to on-line scientific course materials including working with a language that is written right-to-left, different character sets, possible misconceptions and various conventions for expressing equations, variables, units and scientific notation

Characteristics of bladder neoplasms in the young population of Saudi Arabia

Context: Bladder neoplasms are a well-studied subject in medicine. However, the evidence of bladder neoplasms in children and the young adult population (≤40 years), particularly in Saudi Arabia, is lacking. Aims: The aims of this study were to identify histopathological characteristics as well as clinical features, prognosis, and treatment of bladder neoplasms in this age group in a single tertiary referral center, Riyadh, Saudi Arabia. Settings and Design: A retrospective cohort study. Materials and Methods: Children and young adults (≤40 years) diagnosed with epithelial and mesenchymal bladder neoplasms from 1994 to 2017. Statistical Analysis Used: Descriptive data are presented as mean (standard deviation) or median (interquartile range) for continuous variables and n (%) for categorical variables. Statistical Package for Social Sciences version 23 was used. Results: Thirty-eight cases were identified. The majority, 71.1% (n = 27) were male. The median age of diagnosis was 33 years ranging from 1 to 40 years. Nearly 45% (n = 17) were smokers. Macroscopic hematuria was present in 57.8% (n = 22). The most common histopathology was papillary urothelial carcinoma (n = 18, 58%). All mesenchymal neoplasms accounted for 18.4% (n = 7). Of all malignancies, 63.2% (n = 24) and 44.7% (n = 17) were low stage and low grade, respectively. Transurethral resection of bladder tumor (TURBT) was conducted for 81.6% (n = 31). The mean length of follow-up was 36.05 months (±39.4 months). Recurrence occurred in 15.8% (n = 6) and 7.9% (n = 3) had progression. Distant metastasis was reported in 5.3% (n = 2). Nearly 8% (n = 3) died during their follow-up. Conclusions: Bladder malignancies at the early fourth decade of life tend to be a low stage and low grade. The most common histopathology was papillary urothelial carcinoma. Management should be based on the clinical and histopathological features. However, most of the patient underwent TURBT

Implementation of Country-Wide Pharmacoeconomic Principles in Cancer Care in Developing Countries: Expert based recommendations

Background: Cancer care is a major challenge to health care and for optimal outcomes, health systems need to align policy across many areas of public life. The recognition that even the wealthiest nations can fail optimum outcomes indicates a need for increased efficiency in cancer control programs. Fundamental to this is the efficient direction of resources – a process that can be optimised through economic measures.This manuscript contains expert recommendations on how decision maker scan implement pharmacoeconomic principles at national level in developing countries. // Methods: A multidisciplinary panel of 10 experts was formed of oncologists, clinical pharmacists, health economists, chronic disease control and public health experts from different countries and health care sectors. The panel developed consensus recommendations for different stakeholders using a framework analysis methods. // Results: Recommendations were categorized to national level, hospital level, industry level and public- community level to support decisionmakers in implementing pharmacoeconomic principles in a systematic way. The recommendations included having proper well-structured data driven processes with specific role for each stakeholders. We proposed requirement structures and process in such a way that they can be customized based on individual country plans. // Conclusions: The expert panel recommendations will serve as a guide to relevant stakeholders at a country level. Adaptation of these recommendations to each setting is important to accommodate the situation and needs of each country

Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia

Background: Saudi Arabia expedited the approval of some COVID-19 vaccines and launched mass vaccination campaigns. The aim of this study was to describe the demographics of vaccinated COVID-19 cases and compare the mortality rates of COVID-19 cases who were infected post-vaccination in Saudi Arabia. Methods: This was a retrospective cohort study. We retrieved data for COVID-19 cases who were infected pre- or post-vaccination and had received at least one injection of the Oxford–AstraZeneca or Pfizer–BioNTech vaccine from 4 December 2020 to 15 October 2021. Results: The number of patients who were infected and had received at least one dose of a COVID-19 vaccine was 281,744. Approximately 45% of subjects were infected post-vaccination, and 75% of subjects had received the Pfizer–BioNTech vaccine. Only 0.342% of the patients who were infected post-vaccination died, and 447 patients were admitted to ICUs. Most of the patients who were infected with COVID-19 post-vaccination and were admitted to ICUs (69.84%) had received only one dose of the vaccine (p < 0.0001). The mean time to infection for patients who had received one and two doses of the Oxford–AstraZeneca vaccine were 27 and 8 days longer than their counterparts who had received one and two doses of Pfizer–BioNTech vaccine, respectively. No difference in the odds of mortality between the Pfizer–BioNTech and Oxford–AstraZeneca vaccines was found (OR = 1.121, 95% CI = [0.907–1.386], p-value = 0.291). Patients who had received two doses of the vaccine had significantly lower odds of mortality compared to those who had received one dose (p < 0.0001). Conclusions: Vaccines are vital in combating the COVID-19 pandemic. The results of this study show no difference between the Pfizer–BioNTech and Oxford–AstraZeneca vaccines in the rate of mortality. However, the number of vaccine doses was significantly associated with a lower risk of mortality. Future studies should examine the effectiveness of different COVID-19 vaccines using real-world data and more robust designs

Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease

Introduction: The effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment. Methods: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still’s disease. Seventy-seven (51 females and 26 males) patients with Still’s disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent. Results: No statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment. Conclusion: Canakinumab has proved to be effective in patients with Still’s disease, regardless of its line of biologic treatment